Insider trading is the trading of a company’s securities by individuals with access to confidential or material non-public information about the company.
A company is required to report trading by corporate officers, directors, or other company members with significant access to privileged information to the Securities and Exchange Commission (SEC).
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| CorMedix Inc | Janet M. Dillione | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Sep 2026 | 48,909 | 0 | - | - | Phantom Stock | |
| CorMedix Inc | Janet M. Dillione | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Sep 2026 | 48,909 | 117,835 (0%) | 0% | - | Common Stock | |
| Mind Medicine Inc | Andreas Krebs | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Sep 2026 | 1,629 | 0 | - | - | Stock Option (Right to Buy) | |
| Mind Medicine Inc | Andreas Krebs | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 35.52 per share. | 18 Sep 2026 | 1,629 | 21,402 | - | 35.5 | 57,862 | Common Shares |
| Mind Medicine Inc | Carol A. Vallone | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Sep 2026 | 1,086 | 0 | - | - | Stock Option (Right to Buy) | |
| Mind Medicine Inc | Carol A. Vallone | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 35.52 per share. | 18 Sep 2026 | 1,086 | 22,296 | - | 35.5 | 38,575 | Common Shares |
| Sionna Therapeutics Inc | Michael Cloonan | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Sep 2026 | 436,100 | 436,100 | - | - | Non-Qualified Stock Option (right to buy) | |
| Sionna Therapeutics Inc | Michael Cloonan | Director, President & CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 17 Sep 2026 | 436,100 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Caris Life Sciences Inc (Class A) | Brian J. Brille | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 30.33 per share. | 17 Sep 2026 | 400,000 | 230,303 | - | 30.3 | 12,132,080 | Common Stock |
| Caris Life Sciences Inc (Class A) | Brian J. Brille | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.44 per share. | 17 Sep 2026 | 400,000 | 630,303 | - | 2.4 | 976,000 | Common Stock |
| Caris Life Sciences Inc (Class A) | Brian J. Brille | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Sep 2026 | 400,000 | 1,600,000 | - | - | Stock Option | |
| Twist Bioscience Corp | Emily M. Leproust | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 158.09 per share. | 17 Sep 2026 | 232,173 | 673,569 (1%) | 0% | 158.1 | 36,703,672 | Common Stock |
| Sionna Therapeutics Inc | Elena H. Ridloff | CFO and CBO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 17 Sep 2026 | 165,440 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Sionna Therapeutics Inc | Elena H. Ridloff | CFO and CBO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Sep 2026 | 165,440 | 165,440 | - | - | Non-Qualified Stock Option (right to buy) | |
| Sionna Therapeutics Inc | Charlotte McKee | CMO and Head of R&D | Sale or transfer of securities back to the company at price $ 0.00 per share. | 17 Sep 2026 | 155,700 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Sionna Therapeutics Inc | Charlotte McKee | CMO and Head of R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Sep 2026 | 155,700 | 155,700 | - | - | Non-Qualified Stock Option (right to buy) | |
| Twist Bioscience Corp | Emily M. Leproust | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 26.66 per share. | 17 Sep 2026 | 133,269 | 901,696 (2%) | 0% | 26.7 | 3,552,952 | Common Stock |
| Twist Bioscience Corp | Emily M. Leproust | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Sep 2026 | 133,269 | 0 | - | - | Employee Stock Option (right to buy) | |
| Sionna Therapeutics Inc | Michael Cloonan | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Sep 2026 | 109,025 | 656,368 | - | 0 | Common Stock | |
| Sionna Therapeutics Inc | Michael Cloonan | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Sep 2026 | 109,025 | 765,393 | - | 0 | Common Stock | |
| Sionna Therapeutics Inc | Jennifer Fitzpatrick | CLO and Head of Program Mgmt. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Sep 2026 | 103,140 | 103,140 | - | - | Non-Qualified Stock Option (right to buy) | |
| Sionna Therapeutics Inc | Jennifer Fitzpatrick | CLO and Head of Program Mgmt. | Sale or transfer of securities back to the company at price $ 0.00 per share. | 17 Sep 2026 | 103,140 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Soligenix Inc | Robert J. Rubin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Sep 2026 | 78,947 | 78,947 | - | - | Stock Option (Right to Buy) | |
| Soligenix Inc | Gregg Anthony Lapointe | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Sep 2026 | 78,947 | 78,947 | - | - | Stock Option (Right to Buy) | |
| Soligenix Inc | Jerome Bernard Zeldis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Sep 2026 | 78,947 | 78,947 | - | - | Stock Option (Right to Buy) | |
| Soligenix Inc | Diane L. Parks | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Sep 2026 | 78,947 | 78,947 | - | - | Stock Option (Right to Buy) | |
| Twist Bioscience Corp | Emily M. Leproust | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Sep 2026 | 75,439 | 0 | - | - | Employee Stock Option (right to buy) | |
| Twist Bioscience Corp | Emily M. Leproust | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.82 per share. | 17 Sep 2026 | 75,439 | 977,135 (2%) | 0% | 8.8 | 665,372 | Common Stock |
| Kiora Pharma Inc | Keith J. Lane | EVP, Clinical and Regulatory | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Sep 2026 | 55,000 | 55,000 | - | - | Stock Option (right to buy) | |
| Sionna Therapeutics Inc | Charlotte McKee | CMO and Head of R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Sep 2026 | 50,000 | 78,415 | - | 0 | Common Stock | |
| Sionna Therapeutics Inc | Charlotte McKee | CMO and Head of R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Sep 2026 | 50,000 | 128,415 | - | 0 | Common Stock | |
| Sionna Therapeutics Inc | Elena H. Ridloff | CFO and CBO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Sep 2026 | 47,269 | 85,801 | - | 0 | Common Stock | |
| Sionna Therapeutics Inc | Elena H. Ridloff | CFO and CBO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Sep 2026 | 47,268 | 133,069 | - | 0 | Common Stock | |
| Twist Bioscience Corp | Emily M. Leproust | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 157.49 per share. | 17 Sep 2026 | 32,260 | 905,742 (2%) | 0% | 157.5 | 5,080,498 | Common Stock |
| Sionna Therapeutics Inc | Jennifer Fitzpatrick | CLO and Head of Program Mgmt. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Sep 2026 | 28,133 | 28,133 | - | 0 | Common Stock | |
| Sionna Therapeutics Inc | Jennifer Fitzpatrick | CLO and Head of Program Mgmt. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Sep 2026 | 28,132 | 56,265 | - | 0 | Common Stock | |
| Twist Bioscience Corp | Emily M. Leproust | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 159.53 per share. | 17 Sep 2026 | 23,884 | 649,685 (1%) | 0% | 159.5 | 3,810,250 | Common Stock |
| Dianthus Therapeutics Inc | Edward G. Carr | CHIEF ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 17.88 per share. | 17 Sep 2026 | 20,000 | 20,000 | - | 17.9 | 357,600 | Common Stock |
| Dianthus Therapeutics Inc | Edward G. Carr | CHIEF ACCOUNTING OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Sep 2026 | 20,000 | 43,818 | - | - | Stock Option (Right to Buy) | |
| Corcept Therapeutics Inc | G. Charles Robb | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Sep 2026 | 17,493 | 182,507 | - | - | Stock option (right to buy) | |
| Corcept Therapeutics Inc | G. Charles Robb | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.27 per share. | 17 Sep 2026 | 17,493 | 31,156 (0%) | 0% | 8.3 | 144,667 | Common Stock |
| Twist Bioscience Corp | Emily M. Leproust | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 160.44 per share. | 17 Sep 2026 | 14,493 | 635,192 (1%) | 0% | 160.4 | 2,325,245 | Common Stock |
| Twist Bioscience Corp | Emily M. Leproust | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 155.46 per share. | 17 Sep 2026 | 13,378 | 947,099 (2%) | 0% | 155.5 | 2,079,701 | Common Stock |
| Grace Therapeutics Inc | Edward Neugeboren | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Sep 2026 | 12,200 | 12,200 | - | - | Stock Option (Right to Buy) | |
| Grace Therapeutics Inc | Vimal Kavuru | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Sep 2026 | 12,200 | 12,200 | - | - | Stock Option (Right to Buy) | |
| Grace Therapeutics Inc | S. George Kottayil | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Sep 2026 | 12,200 | 12,200 | - | - | Stock Option (Right to Buy) | |
| Twist Bioscience Corp | Emily M. Leproust | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 161.49 per share. | 17 Sep 2026 | 11,169 | 624,023 (1%) | 0% | 161.5 | 1,803,715 | Common Stock |
| United Therapeutics Corp | Martine A. Rothblatt | Director, Chairperson & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 117.76 per share. | 17 Sep 2026 | 9,500 | 333,943 (0%) | 0% | 117.8 | 1,118,720 | Common Stock |
| United Therapeutics Corp | Martine A. Rothblatt | Director, Chairperson & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Sep 2026 | 9,500 | 413,910 | - | - | Stock Option | |
| Twist Bioscience Corp | Emily M. Leproust | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 156.47 per share. | 17 Sep 2026 | 9,097 | 938,002 (2%) | 0% | 156.5 | 1,423,384 | Common Stock |
| United Therapeutics Corp | Paul A. Mahon | EVP & GENERAL COUNSEL | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Sep 2026 | 8,300 | 47,540 | - | - | Stock Option | |
| United Therapeutics Corp | Paul A. Mahon | EVP & GENERAL COUNSEL | Exercise or conversion of derivative security received from the company (such as an option) at price $ 146.03 per share. | 17 Sep 2026 | 8,300 | 53,472 (0%) | 0% | 146.0 | 1,212,049 | Common Stock |
| Dianthus Therapeutics Inc | Edward G. Carr | CHIEF ACCOUNTING OFFICER | Sale of securities on an exchange or to another person at price $ 100.43 per share. | 17 Sep 2026 | 7,928 | 12,072 | - | 100.4 | 796,209 | Common Stock |
| Dianthus Therapeutics Inc | Edward G. Carr | CHIEF ACCOUNTING OFFICER | Sale of securities on an exchange or to another person at price $ 101.37 per share. | 17 Sep 2026 | 6,771 | 5,301 | - | 101.4 | 686,376 | Common Stock |
| Twist Bioscience Corp | Emily M. Leproust | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 152.21 per share. | 17 Sep 2026 | 6,644 | 968,051 (2%) | 0% | 152.2 | 1,011,291 | Common Stock |
| Twist Bioscience Corp | Emily M. Leproust | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 154.17 per share. | 17 Sep 2026 | 4,175 | 960,477 (2%) | 0% | 154.2 | 643,661 | Common Stock |
| Dianthus Therapeutics Inc | Edward G. Carr | CHIEF ACCOUNTING OFFICER | Sale of securities on an exchange or to another person at price $ 102.39 per share. | 17 Sep 2026 | 3,501 | 1,800 | - | 102.4 | 358,467 | Common Stock |
| Twist Bioscience Corp | Emily M. Leproust | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 153.40 per share. | 17 Sep 2026 | 3,399 | 964,652 (2%) | 0% | 153.4 | 521,417 | Common Stock |
| United Therapeutics Corp | Paul A. Mahon | EVP & GENERAL COUNSEL | Sale of securities on an exchange or to another person at price $ 496.58 per share. | 17 Sep 2026 | 2,873 | 49,020 (0%) | 0% | 496.6 | 1,426,662 | Common Stock |
| Twist Bioscience Corp | Emily M. Leproust | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 162.31 per share. | 17 Sep 2026 | 2,565 | 621,458 (1%) | 0% | 162.3 | 416,334 | Common Stock |
| Twist Bioscience Corp | Emily M. Leproust | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 151.46 per share. | 17 Sep 2026 | 2,440 | 974,695 (2%) | 0% | 151.5 | 369,566 | Common Stock |
| United Therapeutics Corp | Martine A. Rothblatt | Director, Chairperson & CEO | Sale of securities on an exchange or to another person at price $ 496.21 per share. | 17 Sep 2026 | 2,182 | 327,507 (0%) | 0% | 496.2 | 1,082,721 | Common Stock |
| United Therapeutics Corp | Martine A. Rothblatt | Director, Chairperson & CEO | Sale of securities on an exchange or to another person at price $ 497.17 per share. | 17 Sep 2026 | 1,953 | 325,554 (0%) | 0% | 497.2 | 970,978 | Common Stock |
| United Therapeutics Corp | Martine A. Rothblatt | Director, Chairperson & CEO | Sale of securities on an exchange or to another person at price $ 495.11 per share. | 17 Sep 2026 | 1,905 | 329,689 (0%) | 0% | 495.1 | 943,183 | Common Stock |
| United Therapeutics Corp | Martine A. Rothblatt | Director, Chairperson & CEO | Sale of securities on an exchange or to another person at price $ 494.34 per share. | 17 Sep 2026 | 1,750 | 331,594 (0%) | 0% | 494.3 | 865,096 | Common Stock |
| United Therapeutics Corp | Paul A. Mahon | EVP & GENERAL COUNSEL | Sale of securities on an exchange or to another person at price $ 495.97 per share. | 17 Sep 2026 | 1,579 | 51,893 (0%) | 0% | 496.0 | 783,132 | Common Stock |
| United Therapeutics Corp | Paul A. Mahon | EVP & GENERAL COUNSEL | Sale of securities on an exchange or to another person at price $ 497.54 per share. | 17 Sep 2026 | 1,400 | 47,620 (0%) | 0% | 497.5 | 696,561 | Common Stock |
| United Therapeutics Corp | Paul A. Mahon | EVP & GENERAL COUNSEL | Sale of securities on an exchange or to another person at price $ 499.75 per share. | 17 Sep 2026 | 1,160 | 45,617 (0%) | 0% | 499.8 | 579,712 | Common Stock |
| Dianthus Therapeutics Inc | Edward G. Carr | CHIEF ACCOUNTING OFFICER | Sale of securities on an exchange or to another person at price $ 103.20 per share. | 17 Sep 2026 | 1,100 | 700 | - | 103.2 | 113,520 | Common Stock |
| Twist Bioscience Corp | Emily M. Leproust | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 163.39 per share. | 17 Sep 2026 | 869 | 620,589 (1%) | 0% | 163.4 | 141,988 | Common Stock |
| United Therapeutics Corp | Paul A. Mahon | EVP & GENERAL COUNSEL | Sale of securities on an exchange or to another person at price $ 498.74 per share. | 17 Sep 2026 | 843 | 46,777 (0%) | 0% | 498.7 | 420,435 | Common Stock |
| Dianthus Therapeutics Inc | Edward G. Carr | CHIEF ACCOUNTING OFFICER | Sale of securities on an exchange or to another person at price $ 104.39 per share. | 17 Sep 2026 | 700 | 0 | - | 104.4 | 73,073 | Common Stock |
| United Therapeutics Corp | Martine A. Rothblatt | Director, Chairperson & CEO | Sale of securities on an exchange or to another person at price $ 493.22 per share. | 17 Sep 2026 | 599 | 333,344 (0%) | 0% | 493.2 | 295,436 | Common Stock |
| SAB Biotherapeutics Inc | Alexandra Kropotova | CHIEF MEDICAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 17 Sep 2026 | 473 | 41,853 | - | - | Common Stock | |
| United Therapeutics Corp | Martine A. Rothblatt | Director, Chairperson & CEO | Sale of securities on an exchange or to another person at price $ 500.09 per share. | 17 Sep 2026 | 468 | 324,603 (0%) | 0% | 500.1 | 234,043 | Common Stock |
| Zoetis (Class A) | Mark Stetter | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Sep 2026 | 342 | 880 | - | - | Phantom Stock Unit | |
| United Therapeutics Corp | Martine A. Rothblatt | Director, Chairperson & CEO | Sale of securities on an exchange or to another person at price $ 499.10 per share. | 17 Sep 2026 | 332 | 325,071 (0%) | 0% | 499.1 | 165,701 | Common Stock |
| United Therapeutics Corp | Paul A. Mahon | EVP & GENERAL COUNSEL | Sale of securities on an exchange or to another person at price $ 501.58 per share. | 17 Sep 2026 | 320 | 45,172 (0%) | 0% | 501.6 | 160,506 | Common Stock |
| Haleon PLC (ADR) | Alan James Stewart | Senior Independent Director | Sale or transfer of securities back to the company at price $ 3.38 per share. | 17 Sep 2026 | 242 | 35,253 (0%) | 0% | 3.4 | 818 | Ords |
| United Therapeutics Corp | Martine A. Rothblatt | Director, Chairperson & CEO | Sale of securities on an exchange or to another person at price $ 501.60 per share. | 17 Sep 2026 | 160 | 324,443 (0%) | 0% | 501.6 | 80,256 | Common Stock |
| United Therapeutics Corp | Martine A. Rothblatt | Director, Chairperson & CEO | Sale of securities on an exchange or to another person at price $ 497.79 per share. | 17 Sep 2026 | 151 | 325,403 (0%) | 0% | 497.8 | 75,166 | Common Stock |
| United Therapeutics Corp | Paul A. Mahon | EVP & GENERAL COUNSEL | Sale of securities on an exchange or to another person at price $ 500.80 per share. | 17 Sep 2026 | 125 | 45,492 (0%) | 0% | 500.8 | 62,600 | Common Stock |
| Clene Inc | David J. Matlin | Director | Grant, award, or other acquisition of securities at price $ 3.28 per share. | 16 Sep 2026 | 434,451 | 912,275 | - | 3.3 | 1,424,999 | common stock |
| Clene Inc | Alison H. Mosca | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 3.28 per share. | 16 Sep 2026 | 198,171 | 478,671 | - | 3.3 | 650,001 | common stock |
| Adaptive biotech Corp | Francis Lo | Chief People Officer | Sale of securities on an exchange or to another person at price $ 28.02 per share. | 16 Sep 2026 | 107,537 | 228,736 (0%) | 0% | 28.0 | 3,013,187 | Common Stock |
| Adaptive biotech Corp | Francis Lo | Chief People Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Sep 2026 | 53,091 | 79,155 | - | - | Stock Option (right to buy) | |
| Adaptive biotech Corp | Francis Lo | Chief People Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.14 per share. | 16 Sep 2026 | 53,091 | 283,804 (0%) | 0% | 12.1 | 644,525 | Common Stock |
| Tenax Therapeutics Inc | Declan Doogan | Director | Purchase of securities on an exchange or from another person at price $ 1.92 per share. | 16 Sep 2026 | 53,000 | 55,274 (0%) | 0% | 1.9 | 101,760 | Common Stock |
| Harmony Biosciences Holdings Inc | Kumar Budur | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 43.05 per share. | 16 Sep 2026 | 35,852 | 13,115 | - | 43.1 | 1,543,590 | Common Stock |
| Skye Bioscience Inc | Andrew J. Schwab | Director, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 1.91 per share. | 16 Sep 2026 | 32,607 | 142,463 (0%) | 0% | 1.9 | 62,279 | Common Stock |
| Harmony Biosciences Holdings Inc | Kumar Budur | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Sep 2026 | 25,446 | 37,500 | - | - | Stock Option | |
| Harmony Biosciences Holdings Inc | Kumar Budur | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 30.27 per share. | 16 Sep 2026 | 25,446 | 48,967 | - | 30.3 | 770,250 | Common Stock |
| Immunic Inc | Robert Thorvald Nagel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Sep 2026 | 25,370 | 25,370 | - | - | Stock Option | |
| Altimmune Inc | Linda M. Richardson | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Sep 2026 | 24,000 | 24,000 (0%) | 0% | 0 | Common Stock, par value $0.0001 | |
| Altimmune Inc | Linda M. Richardson | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Sep 2026 | 24,000 | 72,000 | - | - | Restricted Stock Units | |
| Adaptive biotech Corp | Francis Lo | Chief People Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.12 per share. | 16 Sep 2026 | 23,442 | 336,273 (0%) | 0% | 8.1 | 190,349 | Common Stock |
| Adaptive biotech Corp | Francis Lo | Chief People Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Sep 2026 | 23,442 | 103,142 | - | - | Stock Option (right to buy) | |
| MapLight Therapeutics Inc | Kristopher L. Hanson | General Counsel | Sale of securities on an exchange or to another person at price $ 11.67 per share. | 16 Sep 2026 | 16,509 | 137,044 | - | 11.7 | 192,660 | Voting Common Stock |
| Adaptive biotech Corp | Francis Lo | Chief People Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.99 per share. | 16 Sep 2026 | 15,629 | 312,831 (0%) | 0% | 4.0 | 62,360 | Common Stock |
| Adaptive biotech Corp | Francis Lo | Chief People Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Sep 2026 | 15,629 | 65,636 | - | - | Stock Option (right to buy) | |
| Clene Inc | Robert Etherington | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 3.28 per share. | 16 Sep 2026 | 15,244 | 55,393 | - | 3.3 | 50,000 | common stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 199.30 per share. | 16 Sep 2026 | 13,775 | 253,342 (0%) | 0% | 199.3 | 2,745,402 | Common Stock |
| Adaptive biotech Corp | Francis Lo | Chief People Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Sep 2026 | 13,398 | 24,113 | - | - | Stock Option (right to buy) | |
| Adaptive biotech Corp | Francis Lo | Chief People Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.46 per share. | 16 Sep 2026 | 13,398 | 297,202 (0%) | 0% | 8.5 | 113,347 | Common Stock |
| Avalo Therapeutics Inc | Christopher Ryan Sullivan | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Sep 2026 | 12,394 | 83,848 | - | - | Stock Option (Right to Buy) | |
| Avalo Therapeutics Inc | Christopher Ryan Sullivan | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.88 per share. | 16 Sep 2026 | 12,394 | 52,294 | - | 9.9 | 122,453 | Common Stock |
| Avalo Therapeutics Inc | Christopher Ryan Sullivan | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 16.33 per share. | 16 Sep 2026 | 12,394 | 39,900 | - | 16.3 | 202,437 | Common Stock |
| Roivant Sciences Ltd | James C. Momtazee | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Sep 2026 | 10,531 | 10,531 | - | - | Stock Option (Right to Buy) | |
| Roivant Sciences Ltd | Meghan M. Fitzgerald | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Sep 2026 | 10,531 | 10,531 | - | - | Stock Option (Right to Buy) | |
| Roivant Sciences Ltd | Keith Manchester | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Sep 2026 | 10,531 | 10,531 | - | - | Stock Option (Right to Buy) | |
| Roivant Sciences Ltd | Ilan Oren | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Sep 2026 | 10,531 | 10,531 | - | - | Stock Option (Right to Buy) | |
| Roivant Sciences Ltd | Melissa B. Epperly | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Sep 2026 | 10,531 | 10,531 | - | - | Stock Option (Right to Buy) | |
| Roivant Sciences Ltd | Daniel Gold | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Sep 2026 | 10,531 | 10,531 | - | - | Stock Option (Right to Buy) | |
| Harmony Biosciences Holdings Inc | Kumar Budur | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Sep 2026 | 10,406 | 18,594 | - | - | Stock Option | |
| Harmony Biosciences Holdings Inc | Kumar Budur | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 30.69 per share. | 16 Sep 2026 | 10,406 | 23,521 | - | 30.7 | 319,360 | Common Stock |
| Amphastar Pharma Inc | Rong Zhou | SENIOR EVP, PRODUCTION CENTER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.35 per share. | 16 Sep 2026 | 10,000 | 179,203 (0%) | 0% | 13.4 | 133,500 | Common Stock |
| Amphastar Pharma Inc | Rong Zhou | SENIOR EVP, PRODUCTION CENTER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Sep 2026 | 10,000 | 19,424 | - | - | Employee Stock Option (right to buy) | |
| Amphastar Pharma Inc | Rong Zhou | SENIOR EVP, PRODUCTION CENTER | Sale of securities on an exchange or to another person at price $ 23.94 per share. | 16 Sep 2026 | 10,000 | 169,203 (0%) | 0% | 23.9 | 239,404 | Common Stock |
| PTC Therapeutics Inc | Michael Schmertzler | Director | Sale of securities on an exchange or to another person at price $ 67.83 per share. | 16 Sep 2026 | 9,624 | 1,296,970 (2%) | 0% | 67.8 | 652,796 | Common Stock |
| United Therapeutics Corp | Martine A. Rothblatt | Director, Chairperson & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 117.76 per share. | 16 Sep 2026 | 9,500 | 333,943 (0%) | 0% | 117.8 | 1,118,720 | Common Stock |
| United Therapeutics Corp | Martine A. Rothblatt | Director, Chairperson & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Sep 2026 | 9,500 | 423,410 | - | - | Stock Option | |
| Halozyme Therapeutics Inc | Matthew L. Posard | Director | Sale of securities on an exchange or to another person at price $ 108.04 per share. | 16 Sep 2026 | 8,896 | 62,839 (0%) | 0% | 108.0 | 961,124 | Common Stock |
| Adaptive biotech Corp | Francis Lo | Chief People Officer | Sale of securities on an exchange or to another person at price $ 28.57 per share. | 16 Sep 2026 | 7,869 | 220,867 (0%) | 0% | 28.6 | 224,817 | Common Stock |
| PTC Therapeutics Inc | Michael Schmertzler | Director | Sale of securities on an exchange or to another person at price $ 67.35 per share. | 16 Sep 2026 | 7,006 | 1,306,594 (2%) | 0% | 67.3 | 471,854 | Common Stock |
| Altimmune Inc | Linda M. Richardson | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.24 per share. | 16 Sep 2026 | 6,826 | 17,174 (0%) | 0% | 3.2 | 22,116 | Common Stock, par value $0.0001 |
| Revolution Medicines Inc | Stephen M. Kelsey | See Remarks | Sale of securities on an exchange or to another person at price $ 199.30 per share. | 16 Sep 2026 | 5,484 | 286,307 (0%) | 0% | 199.3 | 1,092,979 | Common Stock |
| Roivant Sciences Ltd | James C. Momtazee | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Sep 2026 | 5,054 | 111,959 | - | 0 | Common Shares | |
| Roivant Sciences Ltd | Meghan M. Fitzgerald | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Sep 2026 | 5,054 | 41,162 | - | 0 | Common Shares | |
| Roivant Sciences Ltd | Keith Manchester | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Sep 2026 | 5,054 | 1,753,457 | - | 0 | Common Shares | |
| Roivant Sciences Ltd | Ilan Oren | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Sep 2026 | 5,054 | 123,680 | - | 0 | Common Shares | |
| Roivant Sciences Ltd | Melissa B. Epperly | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Sep 2026 | 5,054 | 14,954 | - | 0 | Common Shares | |
| Roivant Sciences Ltd | Daniel Gold | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Sep 2026 | 5,054 | 8,965,815 | - | 0 | Common Shares | |
| Inhibrx Biosciences Inc | Jon Faiz Kayyem | Director | Purchase of securities on an exchange or from another person at price $ 100.00 per share. | 16 Sep 2026 | 5,000 | 429,360 | - | 100 | 500,000 | Common Stock |
| Revolution Medicines Inc | Margaret A. Horn | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 199.30 per share. | 16 Sep 2026 | 4,891 | 149,680 (0%) | 0% | 199.3 | 974,792 | Common Stock |
| Halozyme Therapeutics Inc | Matthew L. Posard | Director | Sale of securities on an exchange or to another person at price $ 108.99 per share. | 16 Sep 2026 | 4,000 | 58,839 (0%) | 0% | 109.0 | 435,964 | Common Stock |
| Revolution Medicines Inc | Jack Anders | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 199.30 per share. | 16 Sep 2026 | 3,992 | 119,216 (0%) | 0% | 199.3 | 795,618 | Common Stock |
| Arcutis Biotherapeutics Inc | Masaru Matsuda | See Remarks | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 16 Sep 2026 | 3,674 | 112,508 (0%) | 0% | 25.0 | 91,853 | Common Stock |
| Rallybio Corp | Wendy K. Chung | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.38 per share. | 16 Sep 2026 | 3,562 | 3,562 | - | 2.4 | 8,478 | Common Stock |
| Rallybio Corp | Wendy K. Chung | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Sep 2026 | 3,562 | 0 | - | - | Option (Right to Buy) | |
| Revolution Medicines Inc | Jeffrey Cislini | SVP & General Counsel | Sale of securities on an exchange or to another person at price $ 199.30 per share. | 16 Sep 2026 | 3,314 | 52,541 (0%) | 0% | 199.3 | 660,491 | Common Stock |
| Halozyme Therapeutics Inc | Matthew L. Posard | Director | Sale of securities on an exchange or to another person at price $ 106.13 per share. | 16 Sep 2026 | 3,100 | 74,735 (0%) | 0% | 106.1 | 329,009 | Common Stock |
| Halozyme Therapeutics Inc | Matthew L. Posard | Director | Sale of securities on an exchange or to another person at price $ 106.83 per share. | 16 Sep 2026 | 3,000 | 71,735 (0%) | 0% | 106.8 | 320,484 | Common Stock |
| PTC Therapeutics Inc | Michael Schmertzler | Director | Sale of securities on an exchange or to another person at price $ 66.58 per share. | 16 Sep 2026 | 2,994 | 1,313,600 (2%) | 0% | 66.6 | 199,341 | Common Stock |
| United Therapeutics Corp | Martine A. Rothblatt | Director, Chairperson & CEO | Sale of securities on an exchange or to another person at price $ 502.44 per share. | 16 Sep 2026 | 2,160 | 327,283 (0%) | 0% | 502.4 | 1,085,272 | Common Stock |
| Palvella Therapeutics Inc | Kathleen Goin | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.14 per share. | 16 Sep 2026 | 2,154 | 2,154 | - | 7.1 | 15,380 | Common Stock |
| Palvella Therapeutics Inc | Kathleen Goin | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Sep 2026 | 2,154 | 2,165 | - | - | Stock Option (Right to Buy) | |
| Palvella Therapeutics Inc | Kathleen Goin | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.08 per share. | 16 Sep 2026 | 2,148 | 4,302 | - | 9.1 | 19,504 | Common Stock |
| Palvella Therapeutics Inc | Kathleen Goin | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Sep 2026 | 2,148 | 2,148 | - | - | Stock Option (Right to Buy) | |
| Upstream Bio Inc | Everett Rand Sutherland | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 5.49 per share. | 16 Sep 2026 | 2,095 | 68,717 | - | 5.5 | 11,502 | Common Stock |
| United Therapeutics Corp | Martine A. Rothblatt | Director, Chairperson & CEO | Sale of securities on an exchange or to another person at price $ 498.45 per share. | 16 Sep 2026 | 2,080 | 331,863 (0%) | 0% | 498.5 | 1,036,777 | Common Stock |
| Harmony Biosciences Holdings Inc | Kumar Budur | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 43.01 per share. | 16 Sep 2026 | 1,800 | 13,115 | - | 43.0 | 77,426 | Common Stock |
| Revolution Medicines Inc | Anthony Mancini | See Remarks | Sale of securities on an exchange or to another person at price $ 199.30 per share. | 16 Sep 2026 | 1,747 | 42,116 (0%) | 0% | 199.3 | 348,183 | Common Stock |
| Palvella Therapeutics Inc | Kathleen Goin | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 151.16 per share. | 16 Sep 2026 | 1,659 | 2,643 | - | 151.2 | 250,773 | Common Stock |
| Palvella Therapeutics Inc | Kathleen Goin | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 153.24 per share. | 16 Sep 2026 | 1,654 | 0 | - | 153.2 | 253,465 | Common Stock |
| United Therapeutics Corp | Martine A. Rothblatt | Director, Chairperson & CEO | Sale of securities on an exchange or to another person at price $ 503.53 per share. | 16 Sep 2026 | 1,538 | 325,745 (0%) | 0% | 503.5 | 774,429 | Common Stock |
| Skye Bioscience Inc | Andrew J. Schwab | Director, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 1.91 per share. | 16 Sep 2026 | 1,285 | 5,616 (0%) | 0% | 1.9 | 2,454 | Common Stock |
| United Therapeutics Corp | Martine A. Rothblatt | Director, Chairperson & CEO | Sale of securities on an exchange or to another person at price $ 499.15 per share. | 16 Sep 2026 | 1,220 | 330,643 (0%) | 0% | 499.2 | 608,966 | Common Stock |
| United Therapeutics Corp | Martine A. Rothblatt | Director, Chairperson & CEO | Sale of securities on an exchange or to another person at price $ 504.17 per share. | 16 Sep 2026 | 1,182 | 324,563 (0%) | 0% | 504.2 | 595,932 | Common Stock |
| Palvella Therapeutics Inc | Kathleen Goin | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 152.36 per share. | 16 Sep 2026 | 989 | 1,654 | - | 152.4 | 150,686 | Common Stock |
| Natera Inc | Solomon Moshkevich | PRESIDENT, CLINICALDIAGNOSTICS | Gift of securities by or to the insider at price $ 0.00 per share. | 16 Sep 2026 | 945 | 109,914 (0%) | 0% | 0 | Common Stock | |
| Harmony Biosciences Holdings Inc | Kumar Budur | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 30.69 per share. | 16 Sep 2026 | 900 | 14,015 | - | 30.7 | 27,621 | Common Stock |
| Harmony Biosciences Holdings Inc | Kumar Budur | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Sep 2026 | 900 | 63,346 | - | - | Stock Option | |
| Harmony Biosciences Holdings Inc | Kumar Budur | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Sep 2026 | 900 | 29,400 | - | - | Stock Option | |
| Harmony Biosciences Holdings Inc | Kumar Budur | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 30.27 per share. | 16 Sep 2026 | 900 | 14,915 | - | 30.3 | 27,243 | Common Stock |
| Upstream Bio Inc | Aaron Deykin | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 5.49 per share. | 16 Sep 2026 | 895 | 32,302 | - | 5.5 | 4,914 | Common Stock |
| Upstream Bio Inc | Michael Paul Gray | CFO and COO | Sale of securities on an exchange or to another person at price $ 5.49 per share. | 16 Sep 2026 | 853 | 27,942 | - | 5.5 | 4,683 | Common Stock |
| Harmony Biosciences Holdings Inc | Kumar Budur | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 43.00 per share. | 16 Sep 2026 | 800 | 13,115 | - | 43 | 34,400 | Common Stock |
| United Therapeutics Corp | Martine A. Rothblatt | Director, Chairperson & CEO | Sale of securities on an exchange or to another person at price $ 501.52 per share. | 16 Sep 2026 | 708 | 329,443 (0%) | 0% | 501.5 | 355,077 | Common Stock |
| Upstream Bio Inc | Adam Houghton | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 5.49 per share. | 16 Sep 2026 | 700 | 22,901 | - | 5.5 | 3,843 | Common Stock |
| United Therapeutics Corp | Martine A. Rothblatt | Director, Chairperson & CEO | Sale of securities on an exchange or to another person at price $ 500.20 per share. | 16 Sep 2026 | 492 | 330,151 (0%) | 0% | 500.2 | 246,096 | Common Stock |
| Upstream Bio Inc | Allison Ambrose | General Counsel | Sale of securities on an exchange or to another person at price $ 5.49 per share. | 16 Sep 2026 | 485 | 15,563 | - | 5.5 | 2,663 | Common Stock |
| Harmony Biosciences Holdings Inc | Kumar Budur | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Sep 2026 | 400 | 62,946 | - | - | Stock Option | |
| Harmony Biosciences Holdings Inc | Kumar Budur | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Sep 2026 | 400 | 29,000 | - | - | Stock Option | |
| Harmony Biosciences Holdings Inc | Kumar Budur | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 30.27 per share. | 16 Sep 2026 | 400 | 13,915 | - | 30.3 | 12,108 | Common Stock |
| Harmony Biosciences Holdings Inc | Kumar Budur | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 30.69 per share. | 16 Sep 2026 | 400 | 13,515 | - | 30.7 | 12,276 | Common Stock |
| PTC Therapeutics Inc | Michael Schmertzler | Director | Sale of securities on an exchange or to another person at price $ 68.45 per share. | 16 Sep 2026 | 376 | 1,296,594 (2%) | 0% | 68.4 | 25,737 | Common Stock |
| Revolution Medicines Inc | Alan B. Sandler | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 199.30 per share. | 16 Sep 2026 | 336 | 52,868 (0%) | 0% | 199.3 | 66,966 | Common Stock |
| Corcept Therapeutics Inc | Roberto Wandenkolk Vieira | President, Oncology | Sale of securities on an exchange or to another person at price $ 100.82 per share. | 16 Sep 2026 | 296 | 3,946 (0%) | 0% | 100.8 | 29,843 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 195.01 per share. | 16 Sep 2026 | 213 | 267,117 (0%) | 0% | 195.0 | 41,537 | Common Stock |
| United Therapeutics Corp | Martine A. Rothblatt | Director, Chairperson & CEO | Sale of securities on an exchange or to another person at price $ 505.20 per share. | 16 Sep 2026 | 120 | 324,443 (0%) | 0% | 505.2 | 60,624 | Common Stock |
| Revolution Medicines Inc | Stephen M. Kelsey | See Remarks | Sale of securities on an exchange or to another person at price $ 195.01 per share. | 16 Sep 2026 | 85 | 291,791 (0%) | 0% | 195.0 | 16,576 | Common Stock |
| Revolution Medicines Inc | Margaret A. Horn | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 195.01 per share. | 16 Sep 2026 | 76 | 154,571 (0%) | 0% | 195.0 | 14,821 | Common Stock |
| Revolution Medicines Inc | Jack Anders | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 195.00 per share. | 16 Sep 2026 | 61 | 123,208 (0%) | 0% | 195 | 11,895 | Common Stock |
| Revolution Medicines Inc | Jeffrey Cislini | SVP & General Counsel | Sale of securities on an exchange or to another person at price $ 195.00 per share. | 16 Sep 2026 | 52 | 55,855 (0%) | 0% | 195 | 10,140 | Common Stock |
| Revolution Medicines Inc | Anthony Mancini | See Remarks | Sale of securities on an exchange or to another person at price $ 195.04 per share. | 16 Sep 2026 | 27 | 43,863 (0%) | 0% | 195.0 | 5,266 | Common Stock |
| Revolution Medicines Inc | Alan B. Sandler | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 195.00 per share. | 16 Sep 2026 | 5 | 53,204 (0%) | 0% | 195 | 975 | Common Stock |
| Artiva Biotherapeutics Inc | Fred Aslan | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Sep 2026 | 315,000 | 315,000 | - | - | Employee Stock Option (Right to Buy) | |
| FibroBiologics Inc | Hamid Khoja | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Sep 2026 | 298,508 | 298,508 | - | - | Warrant (Right to Buy) | |
| FibroBiologics Inc | Hamid Khoja | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 1.68 per share. | 15 Sep 2026 | 298,508 | 301,571 | - | 1.7 | 500,001 | Common Stock |
| AN2 Therapeutics Inc | Cameron C Trenor | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Sep 2026 | 233,333 | 233,333 | - | - | Stock Option (right to by) | |
| Travere Therapeutics Inc | Eric M. Dube | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Sep 2026 | 195,841 | 108,493 | - | - | Employee stock option (right to buy) | |
| Travere Therapeutics Inc | Eric M. Dube | Director, CHIEF EXECUTIVE OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 23.34 per share. | 15 Sep 2026 | 195,841 | 628,727 (1%) | 0% | 23.3 | 4,570,929 | Common Stock |
| Whitehawk Therapeutics Inc | David James Lennon | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Sep 2026 | 193,957 | 193,957 | - | - | Restricted Stock Units | |
| Whitehawk Therapeutics Inc | David James Lennon | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Sep 2026 | 193,957 | 193,957 | - | - | Stock option (right to buy) | |
| Whitehawk Therapeutics Inc | David James Lennon | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Sep 2026 | 193,957 | 193,957 | - | - | Restricted Stock Units | |
| Whitehawk Therapeutics Inc | David James Lennon | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Sep 2026 | 193,957 | 193,957 | - | - | Stock option (right to buy) | |
| Whitehawk Therapeutics Inc | Scott Giacobello | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Sep 2026 | 118,476 | 118,476 | - | - | Restricted Stock Units | |
| Whitehawk Therapeutics Inc | Scott Giacobello | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Sep 2026 | 118,476 | 118,476 | - | - | Stock Option (right to buy) | |
| Whitehawk Therapeutics Inc | Scott Giacobello | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Sep 2026 | 118,476 | 118,476 | - | - | Stock Option (right to buy) | |
| Whitehawk Therapeutics Inc | Scott Giacobello | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Sep 2026 | 118,476 | 118,476 | - | - | Restricted Stock Units |
This section tracks all disclosures required by the U.S. Securities and Exchange Commission (SEC) under the Securities Exchange Act of 1934, particularly those related to Section 16 and Rule 10b-5, which govern insider trading activities in the U.S. market. These disclosures are made by corporate insiders, including executives, officers, directors, significant employees, and large shareholders, who are buying and selling stock in their own companies. You can search and filter within these results. You can also sort the information by clicking on the column headers.